Takeda Pharmaceuticals' new French-born CEO knows he is seen as an outsider by many Japanese, including some of Takeda's alumni. He appreciates their concerns and says Takeda will remain a Japanese-based company, true to its heritage. But he also...
Japan's biggest drugmaker Takeda Pharmaceutical Co will become more selective in its choice of research and development projects, its newly appointed president said, as the company struggles with shrinking margins due to a dearth of new...
Christophe Weber, Takeda's anointed next CEO, sees a brighter future through specialization for the Japanese drugmaker, promising to focus only on therapeutic areas where it can lead, leaving behind losing programs.
Takeda Pharmaceutical Co., Ltd (OTCPK:TKPYY)
Q2 2014 Earnings Call
August 01, 2014 5:00 AM ET
Tsudoi Miyoshi – Senior Vice President and Head, Chief Medical & Scientific Officer, Office
François Roger – Chief...
Takeda's board swept aside concerns over having the company run by a non-Japanese executive, setting up Frenchman Christophe Weber to carry out the plans he believes are needed to turn around the faltering drugmaker.
Christophe Weber is next in line for the throne at Takeda, and the former GlaxoSmithKline exec has a mind to grow the Japanese pharma through dealmaking, hoping to refill the in-transition company's pipeline and expand in emerging markets.
Ahead of the annual meeting of Takeda Pharmaceutical, a group of more than 100 shareholders and former employees have expressed their opposition to Takeda's plan to name a Frenchman as its next president.
Oops! Unable to complete your request. Please refresh your browser.